305 related articles for article (PubMed ID: 29715501)
1. Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2.
Jiang J; Xu K; Wang L; Xin W; Zhao G; Huang M; Li S; Luan X; Fang J
Eur J Pharm Sci; 2018 Aug; 121():251-259. PubMed ID: 29715501
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
3. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization.
Zhang M; Yu D; Yang C; Xia Q; Li W; Liu B; Li H
Pharm Res; 2009 Jan; 26(1):204-10. PubMed ID: 18854954
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology Study of the Multiple Angiogenesis Inhibitor RC28-E on Anti-Fibrosis in a Chemically Induced Lung Injury Model.
Kou X; Sun Y; Li S; Bian W; Liu Z; Zhang D; Jiang J
Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31652997
[TBL] [Abstract][Full Text] [Related]
5. Different effects of anti-VEGF drugs (Ranibizumab, Aflibercept, Conbercept) on autophagy and its effect on neovascularization in RF/6A cells.
Wang Y; Yao Y; Li R; Wu B; Lu H; Cheng J; Liu Z; Du J
Microvasc Res; 2021 Nov; 138():104207. PubMed ID: 34119535
[TBL] [Abstract][Full Text] [Related]
6. In vivo characterization of RC28-E, a fusion protein targeting VEGF and bFGF: Pharmacokinetics and ocular distribution in primates.
Jiang J; Wang L; Kou X; Liu Z; Huang M; Li H; Wu C
Exp Eye Res; 2020 Jan; 190():107823. PubMed ID: 31600485
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept.
Hong HK; Park YJ; Kim DK; Ryoo NK; Ko YJ; Park KH; Kim HM; Woo SJ
Invest Ophthalmol Vis Sci; 2020 Nov; 61(13):22. PubMed ID: 33196778
[TBL] [Abstract][Full Text] [Related]
8. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys.
Zhang M; Zhang J; Yan M; Li H; Yang C; Yu D
Mol Vis; 2008 Jan; 14():37-49. PubMed ID: 18246030
[TBL] [Abstract][Full Text] [Related]
9. Both Autocrine Signaling and Paracrine Signaling of HB-EGF Enhance Ocular Neovascularization.
Inoue Y; Shimazawa M; Nakamura S; Takata S; Hashimoto Y; Izawa H; Masuda T; Tsuruma K; Sakaue T; Nakayama H; Higashiyama S; Hara H
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):174-185. PubMed ID: 29191924
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina.
Yang QH; Zhang Y; Jiang J; Wu MM; Han Q; Bo QY; Yu GW; Ru YS; Liu X; Huang M; Wang L; Zhang XM; Fang JM; Li XR
Int J Ophthalmol; 2018; 11(6):935-944. PubMed ID: 29977804
[TBL] [Abstract][Full Text] [Related]
11. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
12. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
13. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
Fauser S; Muether PS
Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.
Koo HC; Baek YY; Choi JS; Kim YM; Sung B; Kim MJ; Kim JG; You JC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918777
[TBL] [Abstract][Full Text] [Related]
15. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
16. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys.
Ren X; Li J; Xu X; Wang C; Cheng Y
Exp Eye Res; 2016 Apr; 145():352-358. PubMed ID: 26919788
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization.
Crespo-Garcia S; Corkhill C; Roubeix C; Davids AM; Kociok N; Strauss O; Joussen AM; Reichhart N
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):4997-5006. PubMed ID: 28979997
[TBL] [Abstract][Full Text] [Related]
18. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
